Jump to content

FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-Fungal R&D

Genedata Selector used as central data hub to store, manage, and analyze complex diagnostic data enabling efficient clinical decision making

September 30, 2014
Basel, Switzerland

Genedata, a leading provider of advanced software solutions for drug discovery and related life science research, today announced that the FUNGITECT consortium has chosen Genedata Selector™ as its host-pathogen data analysis platform for next-generation sequencing (NGS) data. FUNGITECT is a European consortium dedicated to improving the treatment of invasive fungal diseases via individualized anti-fungal drug therapies. Genedata Selector supports this innovative research with a highly-scalable enterprise solution, which supports the integrative analysis of NGS and related experimental data. With Genedata Selector, FUNGITECT researchers can process enormous NGS datasets, extract relevant biological information and transition data to knowledge in support of the consortium’s goals.

Integrated Platform for Fungal Analysis Accelerates Innovative Drug Discovery
Fungal infections represent a significant medical problem, resulting in significant healthcare costs worldwide. Invasive fungal disease is a leading cause of morbidity and mortality in severely immunocompromised individuals such as bone-marrow and organ transplant recipients, preterm neonates, and patients with AIDS. These wide-ranging patient populations require stratified and timely administration of the most appropriate antifungal therapy. FUNGITECT will contribute to the development of such optimized and individualized therapeutic approaches that fight fungal pathogens.

 “Genedata Selector is key to FUNGITECT’s success,” said Prof. Thomas Lion, FUNGITECT’s project coordinator. “The solution will uniquely integrate diagnostically important characteristics of fungal infections, ranging from standardized sample collection to analysis of complex molecular data and result sharing. Genedata Selector’s ability to process big data sets will enable efficient clinical decision-making.”

Using sophisticated algorithms, Genedata Selector will serve as FUNGITECT’s central data management and analysis platform for biomarker development, diagnostics, and therapy support. The platform enables the integration of phenotype and genotype information and offers tools for statistical cross-omics analysis, and will thus facilitate efficient bio-marker prediction and target identification. Designed for scientists and clinicians alike, Genedata Selector:

  • manages molecular profiles of host-pathogen interactions
  • provides tools to assess pathogen resistance mechanisms
  • includes algorithms for rapid host and pathogen profiling
  • reliably predicts biomarkers and molecular targets
  • provides secure web-based data submissions and interactive data analyses

As part of the collaboration with the FUNGITECT consortium, the platform will be further developed to support the integration of existing human susceptibility markers, and re-annotation of genomes as references for functional reconstruction of the host-pathogen systems and their interactions.

“We are excited about our collaboration with the FUNGITECT consortium as it again validates that Genedata Selector can support a wide range of omics-based research projects,” noted Dr. Othmar Pfannes, CEO of Genedata. “Genedata remains committed to supporting innovative research projects with its scalable and modular computational platforms.”

About Genedata

Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube


Rebecca Finck
Public Relations


The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Genedata Selector is key to FUNGITECT’s success

Prof. Thomas Lion
Project Coordinator, FUNGITECT